Cumberland Pharmaceuticals Inc. (CPIX)
USD 4.5
(-6.44%)
USD 4.5
(-6.44%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 52.51 Million USD | -7.79% |
| 2022 | 56.95 Million USD | 36.06% |
| 2021 | 41.85 Million USD | -15.59% |
| 2020 | 49.58 Million USD | -7.25% |
| 2019 | 53.46 Million USD | -6.41% |
| 2018 | 57.12 Million USD | 94.89% |
| 2017 | 29.31 Million USD | 44.5% |
| 2016 | 20.28 Million USD | 34.34% |
| 2015 | 15.09 Million USD | 3.05% |
| 2014 | 14.65 Million USD | 76.07% |
| 2013 | 8.32 Million USD | -36.12% |
| 2012 | 13.02 Million USD | 2.71% |
| 2011 | 12.68 Million USD | -11.55% |
| 2010 | 14.33 Million USD | -54.49% |
| 2009 | 31.5 Million USD | 132.25% |
| 2008 | 13.56 Million USD | 11.43% |
| 2007 | 12.17 Million USD | -20.73% |
| 2006 | 15.35 Million USD | 289.76% |
| 2005 | 3.93 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 54.31 Million USD | 3.43% |
| 2024 Q2 | 52.48 Million USD | -3.37% |
| 2023 Q4 | 52.51 Million USD | 0.81% |
| 2023 Q3 | 52.09 Million USD | -0.84% |
| 2023 Q1 | 53.42 Million USD | -6.2% |
| 2023 Q2 | 52.53 Million USD | -1.65% |
| 2023 FY | 52.51 Million USD | -7.79% |
| 2022 FY | 56.95 Million USD | 36.06% |
| 2022 Q1 | 55.9 Million USD | 33.56% |
| 2022 Q2 | 53.31 Million USD | -4.63% |
| 2022 Q3 | 52.93 Million USD | -0.71% |
| 2022 Q4 | 56.95 Million USD | 7.59% |
| 2021 FY | 41.85 Million USD | -15.59% |
| 2021 Q2 | 41.04 Million USD | -11.68% |
| 2021 Q4 | 41.85 Million USD | 2.28% |
| 2021 Q1 | 46.47 Million USD | -6.29% |
| 2021 Q3 | 40.92 Million USD | -0.29% |
| 2020 Q3 | 48.16 Million USD | -1.93% |
| 2020 Q4 | 49.58 Million USD | 2.96% |
| 2020 FY | 49.58 Million USD | -7.25% |
| 2020 Q1 | 47.57 Million USD | -11.01% |
| 2020 Q2 | 49.11 Million USD | 3.23% |
| 2019 FY | 53.46 Million USD | -6.41% |
| 2019 Q4 | 53.46 Million USD | 2.7% |
| 2019 Q2 | 53.85 Million USD | -9.37% |
| 2019 Q3 | 52.05 Million USD | -3.34% |
| 2019 Q1 | 59.42 Million USD | 4.03% |
| 2018 FY | 57.12 Million USD | 94.89% |
| 2018 Q1 | 30.22 Million USD | 3.1% |
| 2018 Q3 | 29.48 Million USD | -4.18% |
| 2018 Q4 | 57.12 Million USD | 93.72% |
| 2018 Q2 | 30.77 Million USD | 1.83% |
| 2017 FY | 29.31 Million USD | 44.5% |
| 2017 Q2 | 21.3 Million USD | 8.45% |
| 2017 Q1 | 19.64 Million USD | -3.13% |
| 2017 Q4 | 29.31 Million USD | 15.25% |
| 2017 Q3 | 25.43 Million USD | 19.35% |
| 2016 Q1 | 13.88 Million USD | -8.03% |
| 2016 FY | 20.28 Million USD | 34.34% |
| 2016 Q3 | 16.65 Million USD | 23.21% |
| 2016 Q2 | 13.51 Million USD | -2.68% |
| 2016 Q4 | 20.28 Million USD | 21.81% |
| 2015 Q2 | 14.21 Million USD | 10.66% |
| 2015 FY | 15.09 Million USD | 3.05% |
| 2015 Q4 | 15.09 Million USD | 4.02% |
| 2015 Q3 | 14.51 Million USD | 2.11% |
| 2015 Q1 | 12.84 Million USD | -12.33% |
| 2014 Q2 | 12.73 Million USD | 4.86% |
| 2014 Q1 | 12.14 Million USD | 45.95% |
| 2014 Q3 | 13.01 Million USD | 2.22% |
| 2014 FY | 14.65 Million USD | 76.07% |
| 2014 Q4 | 14.65 Million USD | 12.55% |
| 2013 Q2 | 12.59 Million USD | -4.95% |
| 2013 Q3 | 10.97 Million USD | -12.81% |
| 2013 Q4 | 8.32 Million USD | -24.2% |
| 2013 FY | 8.32 Million USD | -36.12% |
| 2013 Q1 | 13.24 Million USD | 1.7% |
| 2012 Q3 | 13.6 Million USD | 11.79% |
| 2012 Q4 | 13.02 Million USD | -4.22% |
| 2012 FY | 13.02 Million USD | 2.71% |
| 2012 Q1 | 12.71 Million USD | 0.29% |
| 2012 Q2 | 12.16 Million USD | -4.35% |
| 2011 Q2 | 13.15 Million USD | -0.25% |
| 2011 Q4 | 12.68 Million USD | 0.49% |
| 2011 Q3 | 12.62 Million USD | -4.06% |
| 2011 FY | 12.68 Million USD | -11.55% |
| 2011 Q1 | 13.18 Million USD | -8.02% |
| 2010 FY | 14.33 Million USD | -54.49% |
| 2010 Q2 | 23.4 Million USD | -6.42% |
| 2010 Q1 | 25 Million USD | -20.63% |
| 2010 Q3 | 15.28 Million USD | -34.68% |
| 2010 Q4 | 14.33 Million USD | -6.19% |
| 2009 Q1 | 12.53 Million USD | -7.6% |
| 2009 Q3 | 30.99 Million USD | 130.13% |
| 2009 Q2 | 13.46 Million USD | 7.46% |
| 2009 Q4 | 31.5 Million USD | 1.64% |
| 2009 FY | 31.5 Million USD | 132.25% |
| 2008 Q4 | 13.56 Million USD | 46.32% |
| 2008 Q3 | 9.27 Million USD | 1.84% |
| 2008 Q1 | 12.39 Million USD | 1.84% |
| 2008 Q2 | 9.1 Million USD | -26.57% |
| 2008 FY | 13.56 Million USD | 11.43% |
| 2007 Q3 | 12.28 Million USD | -9.56% |
| 2007 FY | 12.17 Million USD | -20.73% |
| 2007 Q2 | 13.58 Million USD | -7.15% |
| 2007 Q1 | 14.63 Million USD | -4.72% |
| 2007 Q4 | 12.17 Million USD | -0.92% |
| 2006 Q4 | 15.35 Million USD | 0.0% |
| 2006 FY | 15.35 Million USD | 289.76% |
| 2005 FY | 3.93 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 88.866% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 67.959% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 94.46% |
| Cosmos Health Inc. | 30.25 Million USD | -73.593% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -518.527% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 92.053% |
| Cronos Group Inc. | 43.73 Million USD | -20.075% |
| Incannex Healthcare Limited | 5.83 Million USD | -800.793% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -8.404% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 76.107% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -23824.071% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -755.369% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -755.369% |
| SCYNEXIS, Inc. | 55.45 Million USD | 5.291% |
| Safety Shot Inc | 3.89 Million USD | -1249.322% |
| Theratechnologies Inc. | 98.63 Million USD | 46.759% |
| Alpha Teknova, Inc. | 38.55 Million USD | -36.225% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -281.816% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 92.543% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -499.774% |
| Dynavax Technologies Corporation | 375.02 Million USD | 85.997% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 93.575% |
| Radius Health, Inc. | 804.29 Million USD | 93.47% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -471.039% |
| Alvotech | 1.88 Billion USD | 97.21% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 61.631% |
| SIGA Technologies, Inc. | 57.97 Million USD | 9.419% |
| Shineco, Inc. | 47.6 Million USD | -10.324% |
| Silver Spike Investment Corp. | 3 Million USD | -1644.822% |
| Journey Medical Corporation | 56.49 Million USD | 7.049% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -146.373% |
| Embecta Corp. | 2.03 Billion USD | 97.421% |
| Harrow Health, Inc. | 241.75 Million USD | 78.277% |
| Procaps Group, S.A. | 462.06 Million USD | 88.634% |
| Biofrontera Inc. | 23.13 Million USD | -126.96% |
| DURECT Corporation | 30.4 Million USD | -72.717% |
| PainReform Ltd. | 2.69 Million USD | -1851.55% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 89.227% |
| OptiNose, Inc. | 194.33 Million USD | 72.976% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -150.338% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 71.043% |
| ProPhase Labs, Inc. | 42.54 Million USD | -23.44% |
| Phibro Animal Health Corporation | 725.54 Million USD | 92.762% |
| Procaps Group S.A. | 462.06 Million USD | 88.634% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -274.527% |
| Viatris Inc. | 27.21 Billion USD | 99.807% |
| Rockwell Medical, Inc. | 30.88 Million USD | -70.054% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 41.893% |
| Tilray Brands, Inc. | 892.11 Million USD | 94.113% |
| PetIQ, Inc. | 645.22 Million USD | 91.861% |
| Talphera, Inc. | 6.29 Million USD | -734.916% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 94.848% |
| Alimera Sciences, Inc. | 107.35 Million USD | 51.081% |
| Assertio Holdings, Inc. | 148.41 Million USD | 64.616% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -2669.893% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 69.712% |
| Hempacco Co., Inc. | 18.82 Million USD | -179.009% |
| Alvotech | 1.88 Billion USD | 97.21% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 93.713% |
| Kamada Ltd. | 109.96 Million USD | 52.244% |
| Currenc Group, Inc. | 177.67 Million USD | 70.443% |
| Indivior PLC | 1.95 Billion USD | 97.309% |
| Evoke Pharma, Inc. | 9.64 Million USD | -444.318% |
| Flora Growth Corp. | 17.22 Million USD | -204.937% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -518.527% |
| Evolus, Inc. | 209.68 Million USD | 74.955% |
| HUTCHMED (China) Limited | 536.38 Million USD | 90.209% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 93.988% |
| Akanda Corp. | 12.66 Million USD | -314.529% |